Mesothelioma.com Resources for Patients and their Families
Request Free Guide

Mesothelioma Doctors

Raffit Hassan, MD

Dr. Hassan
Bethesda, MD

Dr. Raffit Hassan

Chief, Thoracic and GI Malignancies Branch & Senior Investigator

National Cancer Institute

Center for Cancer Research
10 Center Drive, Room: 4E-5330
Bethesda, MD 20892
240.760.6232

Need Help Contacting This Doctor?

Dr. Raffit Hassan has held various positions since receiving his medical degree in 1988. Currently, he is a Senior Investigator and Head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute.

One of Dr. Hassan's biggest acheivements recently has been his work with mesothelin targeted immunotherapy. Immunotherapy has shown much promise as an emerging treatment for malignant mesothelioma. Some of Hassan's work has contributed to immunotherapy breakthroughs, such as evaluating mesothelin-directed agents for treating mesothelioma, lung cancer and pancreative cancer.

With his research, Dr. Hassan has been conducting clinical trials with a focus on using an anti-mesothelin immunotoxin, measuring tumor responses in patients with mesothelioma. Results of his research and other studies can be seen through his various publication contributions.

Main Specialty: Medical Oncology

Other Interests & Specialties: Thoracic and gastrointestinal malignancies, targeted immunotherapy, immunotoxins and mesothelin-targeted agents.

Certifications, Awards & Accolades: American Board of Surgery Certification in Surgery, American Board of Thoracic Surgery Certification in Thoracic and Cardiac Surgery, ASCO Career Development Award, NIH Patient Oriented Research Career Development Award, Pioneer Award from the Mesothelioma Foundation

Education & Experience:

Publications:
Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Research. June 2014;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337

Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Science Translational Medicine. October 2013;5(208):208ra147. doi: 10.1126/scitranslmed.3006941

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. December 2010; 16(24): 6132-8. doi: 10.1158/1078-0432.CCR-10-2275

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. September 2007;13(17):5144-9. doi: 10.1158/1078-0432.CCR-07-0869

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. 2006;12(2):447-53. doi: 10.1158/1078-0432.CCR-05-1477

Mesothelioma Clinical Trials by Raffit Hassan, MD

Dr. Hassan is associated with the following clinical trials:

Author: Linda Molinari

Editor in Chief, Mesothelioma Cancer Alliance

Linda Molinari

Reviewer: Annette Charlevois

Patient Support Coordinator

Annette Charlevois
Share
Tweet
Share
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: